antiviral and associated therapy for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
Ivercar-Tuc NCT04701710		RCT	ivermectin	control	COVID-19 prophylaxis (excluding children)	high	117/117	suggested	suggested 87 % decrease in new illness compatible with Covid-19 (PE) but with a low degree of certainty due to high risk of bias
Mikhaylov NCT04405999		RCT	bromhexine	control	COVID-19 prophylaxis (excluding children)	NA	25/25	inconclusive	inconclusive 78 % decrease in new illness compatible with Covid-19 (PE)
Seet 2021 NCT04446104		RCT	ivermectin	vitamin C	COVID-19 prophylaxis (excluding children)	high	617/619	suggested	suggested 97 % decrease in new illness compatible with Covid-19 but with a low degree of certainty due to high risk of bias
NCT04422561 (Shouman) NCT04422561		RCT	ivermectin	standard of care	COVID-19 prophylaxis (excluding children)	high	228/112	suggested	suggested 94 % decrease in new illness compatible with Covid-19 (PE) but with a low degree of certainty due to high risk of bias results from clinicaltrial.gov
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis